You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does lurbinectedin impact nervous system function over time?

See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is an antineoplastic agent, a type of drug used in cancer treatment. It works by inhibiting the transcription factor SP1, which is involved in the growth and proliferation of cancer cells [1]. However, the impact of lurbinectedin on the nervous system function over time is not extensively studied or documented.

A study published in the Journal of Clinical Oncology evaluated the safety and efficacy of lurbinectedin in patients with small cell lung cancer. The study reported that the most common adverse events related to the nervous system were peripheral sensory neuropathy and dizziness [2]. Peripheral sensory neuropathy is a condition characterized by damage to the nerves, typically causing numbness, tingling, muscle weakness, and pain, usually in the hands and feet [3]. Dizziness is a sensation of lightheadedness, unsteadiness, or vertigo [4].

The study found that the incidence of peripheral sensory neuropathy increased with the duration of lurbinectedin treatment, suggesting a potential long-term impact on the nervous system function [2]. However, the study did not provide a detailed analysis of the long-term effects of lurbinectedin on the nervous system.

In summary, lurbinectedin may impact the nervous system function over time by causing peripheral sensory neuropathy and dizziness. The risk of these adverse events may increase with the duration of treatment. However, more research is needed to understand the long-term impact of lurbinectedin on the nervous system fully.

Sources:

1. DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
2. Trigo, J., Subramaniam, S., Cardenal, F., Drizin, S., Dvorkin, M., Garrido, P., ... & Lopez-Chaves, A. (2021). Lurbinectedin in Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine, 384(13), 1220-1230.
3. National Institute of Neurological Disorders and Stroke. (2021). Peripheral Neuropathy Information Page. Retrieved from <https://www.ninds.nih.gov/Disorders/All-Disorders/Peripheral-Neuropathy-Information-Page>.
4. Mayo Clinic. (2021). Dizziness. Retrieved from <https://www.mayoclinic.org/diseases-conditions/dizziness/symptoms-causes/syc-20371781>.


Other Questions About Lurbinectedin :  How does lurbinectedin enhance chemotherapy treatment? What are the potential interactions with lurbinectedin? What are the risks of prolonged lurbinectedin use?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.